A Phase 3 interventional study of PP3M 175 mg eq. and PP3M 263 mg eq. in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 177 sites in 26 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-05-02.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 41 in phase 3, and was the 69th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,429 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 3rd largest by enrollment of the 176 interventional ones that give a count, is one of 7 that started in 2012, is one of 74 in phase 3, and was the 155th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who have been stabilized on PP1M.
This is a randomized (the study drug is assigned by chance), double blind (neither physician nor patient knows the treatment that the patient receives), parallel group (each group of patients will be treated at the same time), multicenter non-inferiority (the effect of the new treatment is not worse than that of the comparison treatment) study. A new formulation of paliperidone palmitate with a 3-month injection interval (PP3M) is being tested for use as maintenance treatment for subjects with schizophrenia who have been first stabilized on paliperidone palmitate with a 1-month injection interval (PP1M). The study consists of 3 phases: a screening/washout/tolerability phase (up to 21 days); a 17-week open-label (all people know the identity of the intervention) stabilization phase (referred to as the Open-label Phase) and a 48-week fixed dose, randomized, double-blind controlled phase (referred to as the Double-blind Phase). After completion of the Screening Phase, all patients will receive PP1M in the Open-label Phase. During this time, flexible dosing will occur at Weeks 5 and 9. At Week 13 patients are to receive the dose of PP1M that was administered at Week 9. Patients who are clinically stable at the end of the Open-label Phase will enter the Double-blind Phase and will be randomly assigned in a 1:1 ratio to receive fixed doses of PP3M or PP1M.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A formulation of paliperidone palmitate with a 3-month injection interval
Drug: PP3M 175 mg eq. · Drug: PP3M 263 mg eq. · Drug: PP3M 350 mg eq. · Drug: PP3M 525 mg eq. · Drug: Placebo (20% Intralipid)
A formulation of paliperidone palmitate with a 1-month injection interval
Drug: PP1M 50 mg eq. · Drug: PP1M 75 mg eq. · Drug: PP1M 100 mg eq. · Drug: PP1M 150 mg eq.
Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase
Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (\>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (\<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (\>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was \<=3 at randomization; had a score of \>=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization.
Time frame: Up to 48 weeks
Change From Double-Blind (DB) Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint
Change From DB Baseline in Clinical Global Impression Severity (CGI-S) Scale Score at Week 48
The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint
Change From DB Baseline in Personal and Social Performance (PSP) Total Score at Week 48
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint
Percentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria
Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed.
Time frame: Weeks 41 to 65
Change From Baseline in Positive and Negative Syndrome Subscales Score at Week 48
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint
Change From Baseline in Marder Factor Subscale Score at Week 48
5 PANSS Marder factor scores (positive symptoms \[range:8 to 56\], negative symptoms \[range: 7 to 49\], disorganized thoughts \[range: 7 to 49\], uncontrolled hostility/excitement \[range: 4 to 28\], and anxiety/depression \[range: 4 to 28\]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia.
Time frame: DB Baseline (Week 17) and 48 week or DB Endpoint
| Milestone | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation |
|---|---|---|---|
| Started | 1429 | 0 | 0 |
| Completed | 1016 | 0 | 0 |
| Not completed | 413 | 0 | 0 |
| Withdrew: Adverse event | 57 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 117 | 0 | 0 |
| Withdrew: Lost to follow-up | 21 | 0 | 0 |
| Withdrew: Withdrawal by subject | 118 | 0 | 0 |
| Withdrew: Excluded from db phase | 70 | 0 | 0 |
| Withdrew: Other | 28 | 0 | 0 |
| Milestone | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation |
|---|---|---|---|
| Started | 0 | 504 | 512 |
| Completed | 0 | 422 | 420 |
| Not completed | 0 | 82 | 92 |
| Withdrew: Adverse event | 0 | 15 | 13 |
| Withdrew: Death | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 7 | 12 |
| Withdrew: Pregnancy | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 50 | 53 |
| Withdrew: Other | 0 | 6 | 12 |
| Withdrew: Blind broken by investigator | 0 | 1 | 0 |
Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (\>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (\<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (\>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was \<=3 at randomization; had a score of \>=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization.
| Percentage of Participants | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase | 91.5 | 90.0 |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
| Units on a scale | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Baseline | 57.4 ± 8.56 | 58.1 ± 8.88 |
| Change from Baseline at DB End point | -3.5 ± 12.50 | -4.3 ± 11.78 |
The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
| Units on a scale | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Baseline | 2.9 ± 0.57 | 2.9 ± 0.66 |
| Change from Baseline at DB End point | -0.1 ± 0.84 | -0.1 ± 0.75 |
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.
| Units on a scale | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Baseline | 65.5 ± 10.40 | 65.0 ± 11.06 |
| Change from Baseline at DB End point | 1.3 ± 10.22 | 1.9 ± 9.21 |
Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed.
| Percentage of Participants | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Percentage of Participants Who Met the Criteria for Symptomatic Remission Based on Andreasen Criteria | 58.4 (0.89 to 1.08) | 59.2 (0.89 to 1.08) |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).
| Units on a scale | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Positive subscale: Baseline | 11.9 ± 3.12 | 12.0 ± 3.19 |
| Positive subscale:Change at Endpoint | -0.6 ± 4.31 | -0.9 ± 3.70 |
| Negative subscale: Baseline | 17.3 ± 4.27 | 17.3 ± 4.11 |
| Negative subscale:Change at Endpoint | -1.4 ± 3.63 | -1.4 ± 3.67 |
| General psychopathology : Baseline | 28.2 ± 4.55 | 28.8 ± 4.79 |
| General psychopathology : Change at Endpoint | -1.4 ± 6.77 | -2.0 ± 6.57 |
5 PANSS Marder factor scores (positive symptoms \[range:8 to 56\], negative symptoms \[range: 7 to 49\], disorganized thoughts \[range: 7 to 49\], uncontrolled hostility/excitement \[range: 4 to 28\], and anxiety/depression \[range: 4 to 28\]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia.
| Units on a scale | Double Blind: Paliperidone Palmitate 3 Month Formulation | Double Blind: Paliperidone Palmitate 1 Month Formulation |
|---|---|---|
| Positive symptoms factor: Baseline | 15.7 ± 3.66 | 15.8 ± 3.88 |
| Positive symptoms factor:Change at Endpoint | -1.1 ± 4.61 | -1.4 ± 4.16 |
| Negative symptoms factor: Baseline | 16.2 ± 4.03 | 16.3 ± 3.90 |
| Negative symptoms factor : Change at Endpoint | -1.4 ± 3.57 | -1.3 ± 3.80 |
| Disorganized thoughts factor :Baseline | 14.2 ± 3.20 | 14.3 ± 3.17 |
| Disorganized thoughts factor:Change at Endpoint | -1.2 ± 3.36 | -1.2 ± 3.24 |
| Uncontrolled hostility Factor:Baseline | 5.2 ± 1.64 | 5.4 ± 1.77 |
| Uncontrolled hostility Factor:Change at Endpoint | 0.2 ± 2.31 | -0.2 ± 2.21 |
| Anxiety/depression factor:Baseline | 6.1 ± 2.02 | 6.3 ± 2.12 |
| Anxiety/depression factor:Change at Endpoint | -0.0 ± 2.69 | -0.2 ± 2.43 |
Collected over From signing of informed consent form up to Follow-Up Visit (4 or 12 Weeks after study drug administration). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | — | 101/1,429 (7.1%) | 457/1,429 (32%) |
| Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | — | 26/504 (5.2%) | 212/504 (42.1%) |
| Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | — | 37/512 (7.2%) | 208/512 (40.6%) |
| Event | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 31/1429 | 12/504 | 11/512 |
| Psychotic DisorderPsychiatric disorders | 14/1429 | 1/504 | 2/512 |
| Suicide AttemptPsychiatric disorders | 3/1429 | 0/504 | 4/512 |
| Hallucination, AuditoryPsychiatric disorders | 6/1429 | 1/504 | 0/512 |
| Suicidal IdeationPsychiatric disorders | 6/1429 | 0/504 | 0/512 |
| Psychiatric SymptomPsychiatric disorders | 4/1429 | 2/504 | 2/512 |
| AnxietyPsychiatric disorders | 4/1429 | 0/504 | 2/512 |
| DelusionPsychiatric disorders | 4/1429 | 1/504 | 2/512 |
| Schizophrenia, Paranoid TypePsychiatric disorders | 0/1429 | 0/504 | 2/512 |
| AkathisiaNervous system disorders | 4/1429 | 0/504 | 0/512 |
| Event | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation |
|---|---|---|---|
| Weight IncreasedInvestigations | 64/1429 | 105/504 | 109/512 |
| Injection Site PainGeneral disorders | 127/1429 | 12/504 | 14/512 |
| NasopharyngitisInfections and infestations | 66/1429 | 36/504 | 33/512 |
| InsomniaPsychiatric disorders | 94/1429 | 16/504 | 24/512 |
| AnxietyPsychiatric disorders | 79/1429 | 27/504 | 22/512 |
| AkathisiaNervous system disorders | 78/1429 | 20/504 | 14/512 |
| HeadacheNervous system disorders | 46/1429 | 18/504 | 26/512 |
| Injection Site IndurationGeneral disorders | 40/1429 | 14/504 | 6/512 |
| Weight DecreasedInvestigations | 10/1429 | 14/504 | 14/512 |
| HypertensionVascular disorders | 11/1429 | 12/504 | 7/512 |
The safety analysis set included all participants who were randomly assigned to treatment during the Double-blind Phase and received at least 1 dose study drug.
| Age, Continuous(years) | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | Total |
|---|---|---|---|
| Mean | 39.0 ± 11.89 | 38.3 ± 12.24 | 38.6 ± 12.06 |
| Sex: Female, Male(Participants) | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | Total |
|---|---|---|---|
| Female | 246 | 231 | 477 |
| Male | 258 | 281 | 539 |
| Region of Enrollment(participants) | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | Total |
|---|---|---|---|
| China | 104 | 106 | 210 |
| Russian Federation | 75 | 75 | 150 |
| Japan | 52 | 56 | 108 |
| United States | 41 | 48 | 89 |
| Ukraine | 35 | 29 | 64 |
| Czech Republic | 31 | 29 | 60 |
| Hungary | 21 | 19 | 40 |
| Poland | 17 | 20 | 37 |
| Argentina | 14 | 16 | 30 |
| Bulgaria | 12 | 16 | 28 |
| Brazil | 13 | 12 | 25 |
| Spain | 11 | 14 | 25 |
| Slovakia | 12 | 10 | 22 |
| Portugal | 11 | 10 | 21 |
| Mexico | 7 | 9 | 16 |
| Taiwan | 7 | 7 | 14 |
| Romania | 7 | 6 | 13 |
| Germany | 8 | 4 | 12 |
| South Korea | 7 | 5 | 12 |
| Belgium | 7 | 4 | 11 |
| Greece | 5 | 6 | 11 |
| Canada | 3 | 6 | 9 |
| Australia | 3 | 2 | 5 |
| France | 1 | 2 | 3 |
| Austria | 0 | 1 | 1 |
Showing the first 100 of 177 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of May 2012, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone
Janssen Research & Development, LLC →